COVID-19
Resources

Lantheus Addresses COVID-19

We remain grateful for the work all health care workers and government officials are doing to keep our communities healthy and safe. We send our thoughts and prayers to those affected by COVID-19 and will continue to do our part to keep our teams and our communities safe and to support our customers and the patients they serve.

View the COVID-19 communications from Lantheus

62%

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes¹

Lantheus Archived Webinar

COVID-19: Clinical Experience with DEFINITY® from
the Front Line in NYC

A question and answer session with Dr. Martin Goldman, Dr. Lori Croft, and Samantha Buckley, RDCS of Mount Sinai Hospital in New York City. They share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic.

Medical Society Resources

American Society of Echocardiography Coronavirus (COVID-19) Resources

LEARN MORE

American College of Cardiology COVID-19 Hub

LEARN MORE

References:

Sperling D, Lai AC, Bienstock SW, et al. Echocardiography in the time of Covid-19: ultrasound enhancing agents save time and augment diagnostic information. Int J Cardiol. 2022;346:100-102. doi:10.1016/j.ijcard.2021.11.040

INDICATION

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY^® administration.
Always have resuscitation equipment and trained personnel readily available.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration.
Always have resuscitation equipment and trained personnel readily available.

CONTRAINDICATIONS:

Contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

WARNINGS AND PRECAUTIONS:

Serious Cardiopulmonary Reactions have occurred during or following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

Serious Hypersensitivity Reactions have been observed during or shortly following administration including anaphylaxis, with manifestations that may include death. DEFINITY® contains PEG and may increase risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG. Clinically assess patients for prior hypersensitivity reactions to products containing PEG. Monitor all patients for hypersensitivity reactions.

Systemic Embolization may occur in patients with a cardiac shunt. Assess patients with shunts for embolic phenomena following administration. DEFINITY® is only for intravenous administration and must not be administered by intra-arterial injection.

There is a risk of Ventricular Arrhythmia Related to High Mechanical Index. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The maximum recommended mechanical index for use with DEFINITY® is 0.8 in adult patients and 0.3 in pediatric patients.

Acute Pain Episodes in Patients with Sickle Cell Disease (SCD) shortly following administration have been reported. Discontinue DEFINITY® in SCD patients experiencing new or worsening pain.

ADVERSE REACTIONS:

The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information and Important Safety Information, including boxed WARNING regarding serious cardiopulmonary reactions.

DEFINITY® Customer Service 1.800.299.3431

BACK TO
TOP

COVID-19Resources

Lantheus Addresses COVID-19

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes1

Lantheus Archived Webinar

Medical Society Resources

INDICATION

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

DEFINITY® Customer Service 1.800.299.3431

DEFINITY® Customer Service 1.800.299.3431

COVID-19
Resources

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes¹

DEFINITY® Customer Service
1.800.299.3431